Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Dignity Made Launches to Fight Trafficking with Ethical Coconut Oil
-
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
-
Golden Goblet Awards Lineup Announced: Spotlight on This Year's Top Contenders
-
TMCI DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securitie
-
ispace Completes Success 8 of Mission 2 Milestones
-
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
-
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Ti
-
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
-
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
-
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
-
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
-
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Pha
-
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Neg
-
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
-
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
-
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
-
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
-
Todd Anniversary: From Research to Reality
-
Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the American So
-
High School Students Named Best in America at the Council for Economic Education’s 2025 National Economics Challenge
-
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
-
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
-
Maryland Student Wins NFTE Capital Youth Entrepreneurship Challenge
-
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
-
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
-
Ocasta’s Frontline Performance Platform: Empowering Employees to Do the Right Thing
-
Robert Clayton: A Pioneer in Fintech and Creator of the AI Wealth Navigation 4.0 System
-
AI Wealth Navigation 4.0: A Milestone in Fintech Innovation
-
Robert Clayton: The Financial Mentor Behind 30,000 Students
-
Ohio Functional Rehab Advances Digital Integration in Multidisciplinary Care for Car Accident Injuries
-
Shout Softly Shirts Announces Launch of New Wearable Art Line Inspired by Master Painters and Social Justice Themes
-
ConcertAI Provides Intelligent Automation of ASCO® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ® SmartLinQ™ Solutions
-
Investors Mobilize to ‘Free Linqto’ Amid Concerns of Mismanagement
-
Zerbe Retirement Community Offers Compassionate Dignified Senior Living in Narvon PA
-
Burlington Security Pros Launches New Website
-
DXL, Now Open In Boca Raton: Clothes That Actually Fit Big + Tall Men Shouldn't Be A Crazy Idea, Right?
-
Infinity Beauty Spa Tukwila Celebrates Exceptional Beauty Services in Tukwila WA
-
Lenoras Healthy Hair Clinic and Spa Unveils Premier Hair Care Services in Cleveland Heights OH
-
JV Micropigmentation & Beauty Elevates Beauty Standards in Rockaway NJ
-
Elvias Salon Continues to Shine as Garner NCs Premier Beauty Salon
-
Beauty Lives Travel Salon LLC Elevates Hair Care Excellence in Atlanta GA
-
Mitch Waldman of Cogent Realty Advisors Announces New Creative Office Spaces Now Available in SoHo Amid Rising Tenant Demand
-
Esthen Exchange Launches Transparency Dashboard and Global Learning Center
-
Hong Kong-headquartered International Mediation Body Established
-
WithSecure has completed the transaction of Cyber security consulting divestment to Neqst
-
Delaware Court Further Extends Topping Period for Citgo Sale Process to June 18, 2025; Confirms Other Deadlines
-
WAO Opens Call for Public Comment on Precautionary Allergen Labelling Recommendations
-
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
-
Oberon Uranium Corp. Completes Sale of Saskatchewan Mineral Claims
-
RCAT INVESTOR NOTICE: Red Cat Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
